موافقات الدواء

PACLITAXEL KABI is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, PACLITAXEL KABI is indicated in combination with cisplatin.
PACLITAXEL KABI is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
PACLITAXEL KABI is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
PACLITAXEL KABI in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
PACLITAXEL KABI is indicated for the second-line treatment of AIDS- related Kaposi’s sarcoma.